Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1184790 | 0.93 | KDM4E (0.66) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL4861758 | 0.89 | SMN1; SMN2 (0.72) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL6997819 | 0.89 | KDM4E (0.63) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL7632830 | 0.88 | KDM4E (0.72) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL10501732 | 0.86 | KDM4E (0.78) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL14085807 | 0.85 | KDM4E (0.76) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL7632095 | 0.83 | KDM4E (0.69) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL7633248 | 0.83 | KDM4E (0.69) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL1281444 | 0.83 | SMN1; SMN2 (0.69) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR | |
| SCHEMBL1039949 | 0.83 | KDM4E (0.69) | KDM4EHSD17B10SMN1; SMN2TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014008214-A1 | BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS | BIOGEN IDEC MA INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | KDM4E 2044/4885HSD17B10 1075/4885SMN1; SMN2 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.